EOLS vs ESTA
EOLS: A global performance beauty company specializing in injectable aesthetic products, primarily botulinum toxin (Jeuveau®) and hyaluronic acid gels (Evolysse™), for the direct-pay medical aesthetics market. ESTA: A global medical technology company revolutionizing the breast aesthetics and reconstruction market through its proprietary, safety-focused Motiva Implants and minimally invasive surgical platforms.
Side-by-side fundamentals
| Metric | EOLS | ESTA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $6.18 | $92.10 | |
| Market cap as of 2026-07-30 | $395M | $2.7B | |
| Net margin as of 2026-07-30 | -14.4% | -19.1% | EOLS higher |
| Gross margin as of 2026-07-30 | +66.1% | +70.1% | ESTA higher |
| Operating margin as of 2026-07-30 | -8.1% | -12.4% | EOLS higher |
| ROE as of 2026-07-30 | -410.2% | -225.9% | ESTA higher |
| ROA as of 2026-07-30 | -19.4% | -12.7% | ESTA higher |
| Debt / equity as of 2026-07-30 | 22.00 | 17.58 | ESTA lower |
| Revenue growth (YoY) as of 2026-07-30 | +9.6% | +34.9% | ESTA higher |
| Revenue CAGR (3y) SEC XBRL | +26.0% | +9.3% | EOLS higher |
| Beta as of 2026-07-30 | 1.39 | 1.10 | |
| 1-year return as of 2026-07-27 close | -35.2% | +117.2% | ESTA higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.